Cholangiocarcinomas Recruiting Phase 2 Trials for Capecitabine (DB01101)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03111732Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)Treatment